Login to Your Account

Other Shoe Drops; Tranzyme Posts Second TZP-102 Miss

By Catherine Shaffer
Staff Writer

Tuesday, December 18, 2012
Just one month after devastating news that its gastroparesis candidate, TZP-102, missed its endpoint in a Phase IIb trial, Tranzyme Pharma Inc., of Research Triangle Park, N.C., reported that its a second Phase IIb trial of the same drug was being discontinued after an interim futility analysis showed a large placebo effect and no treatment effect.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription